• Print
  • Download PDF

Hepatocyte growth factor (HGF) plasma

Test Code: 30143

Cpt Code:

83520 (x1)

Clinical Utility

For the quantitative measurement of Hepatocyte growth factor (HGF). HGF is a potent mitogen for hepatocytes, leading to organ regeneration and wound healing. HGF levels have been shown to be elevated in various liver diseases, reflecting liver damage and dysfunction.

Procedure

The assay for quantification of HGF is a sandwich ELISA performed in a microtiter plate format. Conversion of a chromogenic substrate produces a color, the intensity of which is proportional to the concentration of HGF in the sample material. A standard curve is used to calculate the concentration of HGF in each of the test samples. This test has not been cleared or approved for diagnostic use by the U.S. Food and Drug Administration.

Specificity

Specific to human HGF.

Assay Range

The result is reported in ng/mL. The assay range is approximately 0.6 to 24 ng/mL. The reference range for a healthy population is less than 1.0 ng/mL. However it should be noted that these ranges are obtained from a limited population of apparently healthy adults and are not diagnostic thresholds.

Causes For Rejection

Invalid specimen type, inadequate volume, gross hemolysis or gross lipemia, sample not frozen upon receipt.

Turnaround Time

Test performed M,W,F. TAT 3 - 5 days from receipt of specimen.

Shipping

Ship Monday through Friday. Friday shipments must be labeled for Saturday delivery. All specimens must be labeled with patient's name and collection date. A Viracor-IBT test requisition form must accompany each specimen. Multiple tests can be run on one specimen. Ship specimens FedEx Priority Overnight® to: Viracor-IBT Laboratories, 1001 NW Technology Dr, Lee's Summit, MO 64086.

Specimen Information

Plasma

NY approved. Whole blood should be collected in sodium heparin tubes and plasma separated by centrifugation within 30 minutes of the draw time. 1 mL of plasma sample should be removed to a sterile tube and frozen immediately (-70°C).

Disclaimer

Specimens are approved for testing in New York only when indicated in the Specimen Information field above.

The CPT codes provided are based on Viracor-IBT's interpretation of the American Medical Association's Current Procedural Terminology (CPT) codes and are provided for general informational purposes only. CPT coding is the sole responsibility of the billing party. Questions regarding coding should be addressed to your local Medicare carrier. Viracor-IBT assumes no responsibility for billing errors due to reliance on the CPT codes illustrated in this material.

References

Ferrara JLM, Cooke KR, Teshima T. The Pathophysiology of Acute Graft-versus-Host
Disease. International Journal of Hematology. 2003 78:181-187.

Harris AC, Ferrara JLM, Braun TM, et al. Plasma biomarkers of lower gastrointestinal and liver acute graft-versus-host disease. Blood. 2012 119(12):2960-2963.

Levine JE, Paczesny S, Sarantopoulos S. Clinical Applications for Biomarkers of Acute and
Chronic Graft-versus-Host Disease. Biol Blood Marrow Transplant. 2012 18:S116-S124.

Levine JE, Logan BR, Wu J, et al. Acute graft-versus-host disease biomarkers measured during therapy can predict treatment outcomes: a Blood and Marrow Transplant Clinical Trials Network study. Blood. 2012 119(16):3854-3860.

Paczesny S, Krijanovski OI, Braun TM, et al. A biomarker panel for acute graft-versus-host disease. Blood. 2009 113: 273-278.

<< Back to list